# Background
-   ineffective diuresis and residual volume overload is common and associated with poor outcomes
-   Sequential nephron blockade may be more effective than loop monotherapy
	-  Limited evidence for this
	-   Previous small trial with indapamide
	-   3T trial (2020) - Patients were randomized to oral metolazone, IV chlorothiazide, or tolvaptan therapy. 
	- [JACC 2019](https://www.jacc.org/doi/abs/10.1016/j.jchf.2019.09.012)

# Acetazolamide
-   MOA
	-   CA inhibitor
	-   Reduces prox tubular Na reabsorption
	-   Increases urinary sodium excretion

# Links for reading/opinions

1.  [https://www.tctmd.com/news/old-drug-acetazolamide-offers-new-tricks-acute-hf-advor](https://www.tctmd.com/news/old-drug-acetazolamide-offers-new-tricks-acute-hf-advor)
2.  [https://www.wikijournalclub.org/wiki/ADVOR](https://www.wikijournalclub.org/wiki/ADVOR)
3.  [https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2022/08/26/04/07/ADVOR](https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2022/08/26/04/07/ADVOR)
4.  [https://www.cfrjournal.com/video-index/esc-22-late-breaker-discussion-advor-trial](https://www.cfrjournal.com/video-index/esc-22-late-breaker-discussion-advor-trial)
5.  [http://www.nejm.org/doi/10.1056/NEJMoa2203094](http://www.nejm.org/doi/10.1056/NEJMoa2203094)